Clinical Trial Detail

NCT ID NCT03095612
Title Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Texas Southwestern Medical Center
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Selinexor

Age Groups: adult senior

No variant requirements are available.